Overview

Aranesp® Monthly Preference Study - 2

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).

Phase:

Phase 4

Details

Lead Sponsor:

Amgen

Treatments:

Darbepoetin alfa